CALITHERA BIOSCIENCES INC (CALA) Stock Price, Forecast & Analysis
NASDAQ:CALA • US13089P5070
CALA Key Statistics, Chart & Performance
The current stock price of CALA is 0.3651 USD. In the past month the price decreased by -88.15%. In the past year, price decreased by -96.7%.
CALA Technical Analysis
CALA Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to CALA. CALA has a bad profitability rating. Also its financial health evaluation is rather negative.
CALA Financial Highlights
Over the last trailing twelve months CALA reported a non-GAAP Earnings per Share(EPS) of -12. The EPS increased by 36.17% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | N/A | ||
| ROE | N/A | ||
| Debt/Equity | 0 |
CALA Forecast & Estimates
10 analysts have analysed CALA and the average price target is 5.1 USD. This implies a price increase of 1296.88% is expected in the next year compared to the current price of 0.3651.
For the next year, analysts expect an EPS growth of 69.34% and a revenue growth -100% for CALA
CALA Ownership
CALA Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 15.48 | 397.325B | ||
| AMGN | AMGEN INC | 16.63 | 201.795B | ||
| GILD | GILEAD SCIENCES INC | 16.97 | 187.839B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 23.39 | 120.999B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.78 | 82.427B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 50.19 | 44.414B | ||
| INSM | INSMED INC | N/A | 35.17B | ||
| NTRA | NATERA INC | N/A | 29.514B | ||
| BIIB | BIOGEN INC | 12.62 | 28.182B | ||
| UTHR | UNITED THERAPEUTICS CORP | 16.06 | 20.385B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find more growth stocks the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About CALA
Company Profile
Calithera Biosciences, Inc. is a clinical-stage biopharmaceutical company, which focuses on discovering and developing small molecule drugs that target novel and critical metabolic pathways in tumor and cancer-fighting immune cells. The company is headquartered in South San Francisco, California and currently employs 63 full-time employees. The company went IPO on 2014-10-02. The firm is engaged in developing targeted therapies to redefine treatment for biomarker-specific patient populations. The firm is advancing a robust pipeline of investigational, small molecule oncology compounds with a biomarker-driven approach that targets genetic vulnerabilities in cancer cells to deliver new therapies for patients suffering from aggressive hematologic and solid tumor cancers. The firm is opportunistically developing therapeutics outside of oncology to treat diseases with unmet needs, as is the case in cystic fibrosis. The firm's Mivavotinib is a spleen tyrosine kinase (SYK) inhibitor, which targets the constitutively activated B-cell receptor (BCR) pathway in DLBCL and other non-Hodgkin lymphomas NHLs). Its Sapanisertib is a dual target of rapamycin kinase C I/II (TORC1/2) inhibitor that targets a key survival mechanism in KEAP1/NRF2-mutated tumor cells.
Company Info
CALITHERA BIOSCIENCES INC
343 Oyster Point Blvd #200
South San Francisco CALIFORNIA 94080 US
CEO: Susan M. Molineaux
Employees: 63
Phone: 16508701000.0
CALITHERA BIOSCIENCES INC / CALA FAQ
What does CALA do?
Calithera Biosciences, Inc. is a clinical-stage biopharmaceutical company, which focuses on discovering and developing small molecule drugs that target novel and critical metabolic pathways in tumor and cancer-fighting immune cells. The company is headquartered in South San Francisco, California and currently employs 63 full-time employees. The company went IPO on 2014-10-02. The firm is engaged in developing targeted therapies to redefine treatment for biomarker-specific patient populations. The firm is advancing a robust pipeline of investigational, small molecule oncology compounds with a biomarker-driven approach that targets genetic vulnerabilities in cancer cells to deliver new therapies for patients suffering from aggressive hematologic and solid tumor cancers. The firm is opportunistically developing therapeutics outside of oncology to treat diseases with unmet needs, as is the case in cystic fibrosis. The firm's Mivavotinib is a spleen tyrosine kinase (SYK) inhibitor, which targets the constitutively activated B-cell receptor (BCR) pathway in DLBCL and other non-Hodgkin lymphomas NHLs). Its Sapanisertib is a dual target of rapamycin kinase C I/II (TORC1/2) inhibitor that targets a key survival mechanism in KEAP1/NRF2-mutated tumor cells.
What is the current price of CALA stock?
The current stock price of CALA is 0.3651 USD. The price decreased by -10.95% in the last trading session.
Does CALITHERA BIOSCIENCES INC pay dividends?
CALA does not pay a dividend.
How is the ChartMill rating for CALITHERA BIOSCIENCES INC?
CALA has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
What is the GICS sector and industry of CALA stock?
CALITHERA BIOSCIENCES INC (CALA) operates in the Health Care sector and the Biotechnology industry.
How is the valuation of CALITHERA BIOSCIENCES INC (CALA) based on its PE ratio?
CALITHERA BIOSCIENCES INC (CALA) does not have a PE ratio as the earnings reported over the last twelve months were negative (-12).
Can you provide the market cap for CALITHERA BIOSCIENCES INC?
CALITHERA BIOSCIENCES INC (CALA) has a market capitalization of 1.78M USD. This makes CALA a Nano Cap stock.